Affimed erhält 15,5 Mio. Euro in Series D Finanzierungsrunde

By on Oktober 8, 2012

Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series D financing round of € 15.5 million. The proceeds from this transaction will be used to fund the clinical development of Affimed’s therapeutic pipeline that consists of two TandAb products, AFM11 and AFM13. AFM13, a CD30/CD16A TandAb is currently being evaluated in a phase I clinical trial for the treatment of Hodgkin’s Lymphoma. The results of the trial are expected by December 2012. AFM11 a CD19/CD3 TandAb is in the late stage preclinical development and it is expected to enter phase I clinical studies in 2013. Both candidates have unique properties as shown in preclinical studies… vollständiger Artikel

Mehr Informationen zu dieser und vielen anderen Transaktionen erhalten Sie HIER

Über 25.000 recherchierte Transaktionen seit 2005 - Legen Sie sich Ihre eigene Datenbank zu!

You must be logged in to post a comment Login